Physician profile
Mohammed J Sayed
NPI 1982601795
$3,955.39
in general payments reported to CMS, 2019-2025
31 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,459 · 2020: $784 · 2021: $409 · 2022: $13.25 · 2023: $672 · 2024: $497 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $463.02 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $412.85 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Amarin Pharma, INC. | $383.10 | 2019-2021 | |
| Novo Nordisk INC | $351.75 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $338.12 | 2019-2025 | Farxiga |
| Abbvie INC. | $258.10 | 2019-2024 | Ubrelvy, Vraylar |
| Pfizer INC. | $215.07 | 2019-2025 | |
| Astellas Pharma US INC | $177.19 | 2019-2023 | Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $172.67 | 2019-2024 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.20 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $130.30 | 2019-2023 | Livalo, Seglentis |
| Esperion Therapeutics, INC. | $102.81 | 2020-2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $91.67 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.11 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $66.26 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $65.97 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $62.01 | 2019 | |
| Exact Sciences Corporation | $58.37 | 2024-2025 | Cologuard Collection Kit |
| Biogen, INC. | $50.93 | 2020-2021 | |
| Glaxosmithkline, LLC. | $46.48 | 2024 | Trelegy Ellipta |
| Bausch Health US, LLC | $41.82 | 2019-2020 | |
| Allergan, INC. | $39.98 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.88 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.98 | 2019 | |
| Currax Pharmaceuticals LLC | $27.85 | 2020-2023 | Contrave |
| Shire North American Group INC | $15.32 | 2019 | |
| Ge Healthcare | $14.94 | 2020 | |
| Sumitomo Pharma America, INC. | $14.92 | 2024 | Gemtesa |
| Eisai INC. | $12.09 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.76 | 2019 | |
| Horizon Therapeutics Plc | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Sayed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.